Main Article Content
Aims: To assess the efficacy and fetomaternal safety of atosiban among Indian pregnant women presenting with preterm labor.
Study Design: Prospective, open-label, multicentric, non-comparative, phase-IV clinical study.
Place and Duration of Study: Department of Obstetrics and Gynaecology at nine hospitals across India from October 2016 to December 2019.
Methodology: A total of 212 pregnant women admitted with preterm labour between 24 and 36 weeks of gestation were administered intravenous atosiban up to 48 hours. Efficacy was defined as the successful delay of delivery without the need of an additional or alternative tocolytic agent for 72 hours. Safety was evaluated by recording the occurrence of adverse events in the mother, fetus and neonate.
Results: Tocolytic efficacy of Atosiban was 84.88% at 48 hours and 74.15% at day 7 without additional tocolytic agent or retreatment after 48 hours. The mean number of days gained after the start of atosiban tocolysis were 29.15 ± 1.82 days with mean gestational age at delivery of 35.1 ± 3.33 weeks. Atosiban reduced the frequency of contractions from 4.3 ± 1.47 to 0.67 ± 1.13 contractions/30 min at 72 hours. The proportion of neonates with birth weights more than 2,500 gm was 41.67%. A total of 205 neonates out of 216 (94.95%) had APGAR score more than 7 after 5 minute. Atosiban successfully delayed the labour in 92.31% (n=13) of “Twin pregnancy” patients for 48 hours and beyond 7 days in 9 patients (69.2%). There were no serious adverse events reported.
Conclusions: In patients with threatened preterm birth, 48 hour tocolysis with atosiban was found to be safe and effective in preventing imminent preterm birth even when it was a twin pregnancy or associated with co-morbidities. Atosiban showed favorable side effects profile and improved the perinatal outcomes.
Clinical Trial Registry of India Number: CTRI/2017/03/008065;
WHO [Internet]. Preterm birth fact sheets. 2018 February 19 [cited 07 August 2020]. Available:https://www.who.int/news-room/fact-sheets/detail/preterm-birth
Lamont RF, Jørgensen JS. Safety and efficacy of tocolytics for the treatment of spontaneous preterm labour. Curr Pharm Des. 2019;25(5):577-92. DOI:10.2174/1381612825666190329124214
Ali AA, Sayed AK, El Sherif L, et al. Systematic review and meta-analysis of randomized controlled trials of atosiban versus nifedipine for inhibition of preterm labor. Int J Gynaecol Obstet. 2019;145(2):139-48. DOI:10.1002/ijgo.12793
Kim SH, Riaposova L, Ahmed H, et al. Oxytocin receptor antagonists, atosiban and nolasiban, inhibit prostaglandin f2α-induced contractions and inflammatory responses in human myometrium. Sci Rep. 2019;9, 5792. Available:https://doi.org/10.1038/s41598-019-42181-2
He Y, Wu H, He X, et al. Application of atosiban in frozen-thawed cycle patients with different times of embryo transfers. Gynecol Endocrinol. 2016;32(10):811-15. DOI:10.1080/09513590.2016.1180680
Li J, Chen Y, Wang A, Zhang H. A meta-analysis of atosiban supplementation among patients undergoing assisted reproduction. Arch Gynecol Obstet. 2017; 296(4):623-34. DOI: 10.1007/s00404-017-4455-0
Lamont CD, Jørgensen JS, Lamont RF. The safety of tocolytics used for the inhibition of preterm labour. Expert Opin Drug Saf. 2016;15(9):1163-73. DOI:10.1080/14740338.2016.1187128
Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. Int J Womens Health. 2010;1:73-84. DOI:10.2147/ijwh.s4730
van Vliet EOG, Nijman TAJ, Schuit E, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): A multicentre, randomised controlled trial. Lancet. 2016;387(10033):2117-24. DOI:10.1016/S0140-6736(16)00548-1
Shaikh S, Mayekar R, Bhosale A, Nandanwar Y, Dewan B. Atosiban– Its impact on uterine activity in preterm labour. BJMMR. 2016;18(2):1-8. Article no.BJMMR.28846.
Dewan B, Shah D. The clinical experience of atosiban in preterm labour. BJMMR. 2016; 13(7):1-9. Article no.BJMMR.23823.
Husslein P, Cabero Roura L, Dudenhausen JW, et al. Atosiban versus usual care for the management of preterm labor. J Perinat Med. 2007;35(4):305-13. DOI:10.1515/JPM.2007.078
Berger R, Abele H, Bahlmann F, Bedei I, Doubek K, Felderhoff-MüserU, et al. Prevention and therapy of preterm birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF registry number 015/025, february 2019) - Part 2 with recommendations on the tertiary prevention of preterm birth and the management of preterm premature rupture of membranes. Geburtshilfe Frauenheilkd. 2019;79(8):813-33. DOI: 10.1055/a-0903-2735.
Helmer H, Brunbauer M, Rohrmeister K. Exploring the role of tractocile in everyday clinical practice. BJOG. 2003;110(20):113-15. DOI:10.1016/s1470-0328(03)00056-9
Husslein P. Development and clinical experience with the new evidence-based tocolytic atosiban. Acta Obstet Gynecol Scand. 2002;81(7):633-41. DOI:10.1034/j.1600-0412.2002.810709.x
Salim R, Garmi G, Nachum Z, Zafran N, Baram S, Shalev E. Nifedipine compared with atosiban for treating preterm labor: A randomized controlled trial. Obstet Gynecol. 2012;120(6):1323-31. DOI: 10.1097/aog.0b013e3182755dff
Khalil MA, Saad R, Ibrahim AA. Initial cervical dilation and the association of the success of atosiban. Int J Pregn & Chi Birth. 2019;5(2):103-6. DOI: 10.15406/ipcb.2019.05.00156
Moutquin JM, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: A multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000;182(5):1191-99. DOI:10.1067/mob.2000.104950
Y.-J. Xu, L.-M. Ran, S.-S. Zhai, X.-H. Luo, Y.-Y. Zhang, Z.-Y. Zhou, et al. Clinical efficacy of atosiban treatment in late abortion and preterm labour of twin pregnancy. Eur Rev Med Pharmacol Sci. 2016; 20(9):1881-87.
Mariavittoria L, Giovanni N, Marilena M, Raffaella I, Emilia S, et al. Two cycles of atosiban in preventing preterm birth in twin pregnancies. Clin Obstet Gynecol Reprod Med. 2016;2. DOI: 10.15761/COGRM.1000155
de Heus R, Mol BW, Erwich JJ, et al. Adverse drug reactions to tocolytic treatment for preterm labour: Prospective cohort study. BMJ. 2009;338:b744. DOI:10.1136/bmj.b744
Husslein P, Roura LC, Dudenhausen J, Helmer H, Frydman R, Rizzo N, et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG. 2006;113(3): 105-10. DOI: 10.1111/j.1471-0528.2006.01134.x.
Valenzuela GJ, Craig J, Bernhardt MD, Holland ML. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol. 1995;172(4Pt1):1304-06. DOI:10.1016/0002-9378(95)91497-8
Grzesiak M, Wilczynski J. Preliminary report of 48-hours atosiban administration in spontaneous preterm labor-doppler blood flow assessment of placental and fetal circulation. Neuro Endocrinol Lett. 2013;34(7):681-86.
Weissman A, Tobia RS, Burke YZ, Maxymovski O, Drugan A. The effects of oxytocin and atosiban on the modulation of heart rate in pregnant women. J Matern Fetal Neonatal Med. 2017;30(3):329-33. DOI:10.3109/14767058.2016.1172564
Coomarasamy A, Knox EM, Gee H, Khan KS. Oxytocin antagonists for tocolysis in preterm labour-- A systematic review. Med Sci Monit. 2002;8(11):RA268-73
Wielgoś M, Bomba-Opoń DA. [Tocolysis in preterm labour--current recommendations]. Ginekol Pol. 2014;85(5):332-34. DOI:10.17772/gp/1732
Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour. Drugs. 2004;64(4):375-82.